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ABSTRACT  
Objective: Develop an effective and stable tablet form of Liu Wei Di Huang (LWDH).  
Methods: LWDH extract was obtained by decoction (TC) and reflux with water (WR). Extracts were concentrated and analyzed by HPLC-PDA using 
loganin as the bioactive marker. Adsorbents, tablet strength and friability, and tablet quality and stability were evaluated.  
Results: Extraction of LWDH formula from raw materials using WR yielded higher concentrations of loganin than TC. The best formulation of 
LWDH tablets included Avicel®PH101, corn starch, purified talcum, magnesium stearate and Cab-osil®
Conclusion: Extraction of LWDH formula using reflux with water produces higher yields than decoction. A suitable tablet formulation consists of 
dried water extract (38.83 %), corn starch (29.13 %), Avicel
 with about 97.40 % of the label amount of 
active marker. Excluding moisture from the product reduced marker degradation, suggesting a product shelf life 12+months. Finished tablets were 
uniform in weight, friability, disintegrated in<30 min, had good microbial and heavy metal contamination safety profiles and was stable.  
®PH101 (29.13 %), purified talcum (0.97 %), magnesium stearate (0.97 %) and Cab-
osil®
Keywords: Liu Wei Di Huang, Chinese Traditional medicine, Tablets, Quality, Stability. 
 (0.97 %) prepared by wet granulation. Excluding moisture from the product reduces product degradation, suggesting a shelf life of 
12+months. LWDH tablets avoid traditional formulation problems (high dosages, unacceptable taste and odor, lack of product uniformity, 
contamination with microorganisms and heavy metals), and are a good alternative for patients and TCM practitioners. 
 
INTRODUCTION 
Traditional Chinese medicine (TCM) is a popular form of alternative 
medicine which provides supplements as well as treatments for some 
chronic diseases or conditions. Treatments are based on the 
relationship of yin and yang (阴阳), five phases (五行) and Qi (氣) [1]. 
Most TCM textbooks and TCM teachers mention that kidney deficiency 
in women relates to a menopause disorder [2]. Liu Wei Di Huang (六味
地黄/lWDH) is one of the TCM herbal formulas used in the treatment 
of menopause problems caused by kidney yin deficiency [3-4]. The 
LWDH formula consists of six kinds of crude drugs: Shudihuang (熟地
黄) from Rehmannia gultinosa, Shanshuyu (山茱萸) from Cornus 
officinalis, Shanyao (山药) from Dioscorea Opposite, Zexie (泽泻) from 
Arisma orientale, Fuling (茯苓) from Wolfiporia extensa and Danpi (丹
皮) from Paeonia suffruticoas [3-6] (fig. 1). The Pharmacopoeia of the 
People's Republic of China (2005) describes two traditional dosage 
forms: Liu Wei Di Huang Wan (六味地黄丸) which is a pill form (Wan 
丸 = pills) and Liu Wei Di Huang Keli (六味地黃顆粒) which is a 
granulate form (Keli 顆粒 = granules). The dosages are 27 g/day for 
pills or 15 g/day for granules, taken in three equal doses of 9 g and 5 g, 
respectively. The loganin content in both forms should not be lower 
than 4.5 mg/dose [5]. In addition to pills and granules, LWDH formula 
can be prepared as a solution obtained by decoction [3, 6].  
 
Fig. 1: Crude drugs in the liu wei di huang formula: Shudihuang (A), 
Shanzhuyu (B), Shanyao (C), Zexia (D), Fuling (E) and Danpi (F) 
The traditional dosage forms have disadvantages such as being 
inconvenient to use, having an unacceptable taste or odor, and 
having variations of content uniformity as well as contamination 
with microorganisms and heavy metals [7-8]. This study attempted 
to develop an LWDH formula in tablet dosage form which avoids 
those disadvantages.  
MATERIALS AND METHODS 
Materials 
Raw materials used in preparing the Liu Wei Di Huang formula were 
purchased from the Vejpong Pharmacy Co., Ltd. (Thailand). Avicel® 
PH101 was purchased from DMV-Fonterra Excipients GmbH & Co. 
KG (Germany). Corn starch was purchased from CM Chemical & Lab 
Supply (Thailand). Cab-osil®
Apparatus 
 was purchased from Sigma-Aldrich 
(Germany). Magnesium stearate was purchased from Riedel-de 
Haen (Germany). Purified talcum was purchased from Ilshin 
Industrial Co., Ltd. (China). Loganin CRS, 5-(hydroxymethyl)-furfural 
CRS, ursolic acid CRS and paeonol CRS were purchased from Fluka 
(Germany). Acetonitrile HPLC grade, ethanol HPLC grade, 
phosphoric acid AR grade and 95 % ethanol AR grade were 
purchased from RCI Labscan (Thailand). 
Chromatographic analysis was carried out using an HPLC system 
(Shimadzu, Japan) with degasser (DGU-20A5), pump (LC-20AD), 
autosampler (SIL-20AC), column oven (CTO-20A), diode array 
detector (SPD-M20A) and communication bus module (CBM-20A). 
Columns used in this study were Inertsil ODS-3 C18 reversed phase 
columns. Chromatograms were analyzed using LC Solutions software. 
Evaluation of the quality of the crude drugs  
Raw materials, the crude drugs used in producing the LWDH 
formula, were evaluated in the areas of physical characteristics, 
chemical identification, water content, total ash, acid-insoluble ash, 
extractive value and chemical content following the Chinese 
Pharmacopoeia (2005) [5]. 
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Extraction of liu wei di huang 
The crude drugs Shudihuang, Shanzhuyu, Shanyao, Zexie, Fuling and 
Danpi were measured in proportions of 24:12:12:9:9:9 to make up a 
total weight of 75.0 g, then they were mixed together. The LWDH 
formula was extracted using two different methods: decoction 
imitating traditional procedures and reflux with water. The water 
extracts obtained by each of the two extraction methods were 
concentrated separately by rotary evaporator. 
Dose calculation of liu wei di huang water extract 
Standard preparation [5] 
Loganin CRS a form of iridoid glycoside (fig. 2), was prepared in 50 
% ethanol at a concentration of 0.224 mg/ml. The solution was 
filtered through a 0.45 micron nylon membrane filter then injected 
into an HPLC-PDA by an autosampler with a 10 µl loop. 
 
 
Fig. 2: Chemical structure of iridoids (A) and loganin (B) 
 
Sample preparation 
The water extracts obtained from decoction (TC) (1.5100 g) and 
reflux with water (WR) (1.0000 g) were dissolved in 40 ml of 50 % 
ethanol, weighed, sonicated for 30 min, allowed to cool and then 
weighed again for impletion of evaporated solvent. The sample 
solutions were filtered using Whatman No.1 filter paper. The 
samples, 5 ml of filtrate made up to 10 ml in a volumetric flask, were 
filtered using a 0.45 micron nylon membrane filter and then injected 
in volumes of 100 l to HPLC-PDA by an autosampler [5, 9]. 
Chromatographic analysis system  
The chromatographic system used was modified from the methods 
of Xie et al. [9] and the Pharmacopoeia of the People's Republic of 
China (2005) [5]. The stationary phase used C18 reversed phase 
silica gel and the mobile phase used a mixture of acetonitrile (line A) 
and 0.015 % phosphoric acid (line B). The flow system was a 
gradient system: 0-3 min–(start) isocratic line A = 5 %; 3-30 min–
gradient line A to 60 %; 30-33 min–gradient line A to 70 %; 33-49 
min–isocratic line A = 70 %; 49-50 min–gradient line A to 5 %; 50-
60 min (stop)–isocratic line A = 5 %. Flow rate of the system was 1 
ml/min. The column was temperature controlled at 35 °C and the 
detection wavelength was 236 nm. Three replications were carried 
out for each sample of LWDH water extract.  
Calculation of drug dosing from LWDH extract  
The approximate dosage (AD) of Liu Wei Di Huang extract, 
measured to equal the dose of traditional dosage forms, was 
calculated by comparing loganin content. The water extract with the 
higher loganin content per gram of extract, i.e., the lower dose, was 
selected to be an active ingredient in the development of the LWDH 
tablets.  
Development of tablets from LWDH extract 
Adsorbent selection 
LWDH extract was divided into three batches of 500–600 mg 
each and put into three mortars. Three different types of 
adsorbent, corn starch, lactose and Avicel®
Development of tablet formulation 
 PH101, all commonly 
used in the manufacture of Chinese herbal medicines [10], were 
put on individual watch glasses. The combined weight of the 
watch glass plus adsorbent was recorded (weight A). The 
adsorbents were evaluated for their adsorptibility by adding 
quantities of each type into one of the mortars and slowly mixing 
that with the extract until the extract powder appeared clearly. 
The watch glass and the remaining adsorbent were weighed 
(weight B). The quantity of each type of adsorbent used for 
powder reformation was calculated as the difference between 
weight A and weight B. Adsorbents with an adsorption ratio of 
not more than 1:2 were selected as the excipients for 
development of tablet formulation.  
LWDH extract was weighed and mixed with the adsorbents to 
obtain a wet mass appearance with the geometric dilution 
technique using a mortar and pestle. The wet mass was passed 
through a No. 8 sieve to obtain wet granules [11] which were dried 
in a hot air oven at 50 °C (below the 65 °C swelling temperature of 
corn starch [12]) until loss on drying was not more than 5 % (in 
the case of Avicel®, not more than 7 % [12]) to achieve 
appropriate tablet compressibility [11]. The granules were passed 
through a No. 12 sieve using an oscillating granulator [11, 13] to 
obtain dry granules. Purified talcum, magnesium stearate and Cab-
osil®
Evaluation tablet quality  
, each weighing 1 % of the weight of the finished granules, 
was then mixed with the finished granules by tumbling for 1 min. 
The mixture was compressed by a single stroke tablet machine to 
create the finished tablets. The tablets were then evaluated for 
friability and disintegration time to evaluate the effect of 
adsorbents on those parameters. Adjustments to the tablet 
formulation were made based on the evaluation results. 
The tablets with a suitable formulation were evaluated for quality 
based on physical appearance, weight variation, friability, hardness, 
disintegration time, loganin (marker) content, plus microbial and 
heavy metal contamination, quality parameters provided by the Thai 
FDA guidelines for finished herbal products [14]. 
Stability evaluation of tablets from LWDH extract  
Tablets were packaged in two types of container: either in glass 
bottles with light protection (container B) or in laminated, heat 
sealed packages which were then inserted into glass bottles with 
light protection (container L). Containers were kept in a stability 
chamber either at the standard conditions of 30 °C and 65 % relative 
humidity (RH) or at accelerated conditions of 40 °C and 75 % RH. 
Samples were evaluated for appearance, hardness, friability, 
disintegration time and loganin content on day 0 and then again at 
day 30 and day 90.  
RESULTS AND DISCUSSION  
Raw materials used in preparation of the LWDH formula were 
purchased from herbal drug stores in Thailand; quality was 
evaluated following the Chinese Herbal Pharmacopoeia (2005) [5]. 
Macroscopic and microscopic characteristics of all crude drugs 
were in accordance with the herbal monograph in that document. 
The chemical identification of Shudihuang, Shanzhuyu and Danpi 
was made with the Thin Layer Chromatographic (TLC) technique 
using 5-(hydroxymethyl)-furfural, ursolic acid and paeonol as 
chemical markers (see chemical structures in fig. 3). TLC 
chromatograms of three of the herbal medicines showed that all 
samples contained the specified chemical components as 
described in the herbal monograph (fig. 4). 5-(hydroxymethyl)-
Furfural (Retard factor (Rf) = 0.6) was found in Shudihuang, 
Shanzhuyu contained Ursolic acid (Rf = 0.6), and paeonol (Rf = 0.7) 
was found in Danpi. All crude drugs in the LWDH formula were 
identified by macroscopic and microscopic inspection and 
confirmed by chemical identification. Parameters evaluated for all 
the crude drugs included water content, total ash, acid-insoluble 
ash, extractive value and chemical content [5]. The results (table 
1) show that all the samples were of standard quality as specified 
in the Chinese Herbal Pharmacopoeia (2005) [5].  
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Fig. 3: Chemical structure of 5-(hydroxymethyl)-furfural (A), 
ursolic acid (B) and paeonol (C) 
 
 
Fig. 4: TLC chromatograms of Shudihuang (A), Shanzhuyu (B) 
and Danpi (C) 
 
The LWDH formula extracted by the reflux method gave higher 
yields than decoction (65 % vs 55 % by weight). Water extracts 
obtained from the two different methods were analyzed for chemical 
content by HPLC-PDA with loganin used as the chemical marker [5, 
9]. Loganin was appeared in HPLC chromatograms at retention time 
of 16.8 min (fig. 5). Because loganin was specified as the chemical 
marker in the LWDH formula with a percentage label amount per 
dose, loganin content can be used to calculate drug dosing from 
LWDH water extracts. Using the HPLC chromatograms, loganin 
content of LWDH water extracts was calculated by area under curve 
(AUC) comparison (table 2). It was found that the WR extract 
contained a higher loganin content per gram of extract than the TC 
extract. For that reason, WR extract was selected to be an active 
ingredient in the development of LWDH tablets.  
 
Fig. 5: HPLC chromatograms of TC and WR 
 
Table 1: Quality of crude drugs used 
Plant name Parameter 
Water Content ( %) Total Ash ( %) Acid-insoluble Ash ( %) Extractive Value ( %) Marker Content ( %)** 
Shudihuang n/a 5.55 (≤6.0)* 1.91 (≤2.0)* 69.37 (≥60.0)* n/a 
Shanzhuyu 7.99 (≤16.0)* 4.90 (≤6.0)* 0.42 (≤0.5)* 55.07 (≥50.0)* 0.74 (≥0.6)* 
Shanyao n/a n/a n/a n/a n/a 
Zexie n/a 2.71 (≤5.0)* 0.13 (≤0.5)* n/a n/a 
Fuling 6.77 (≤15.0)* 0.25 (≤4.0)* 0.03 (≤2.0)* n/a n/a 
Danpi 6.75 (≤13.0)* 3.59 (≤5.0)* 0.28 (≤1.0)* 15.63 (≥15.0)* 1.33 (≥1.2)* 
n/a = Data not provided in the monograph, *The upper limit or lower limit of crude drugs as specified in the monograph, **Standard markers: 
loganin for Shanzhuyu and paeonol for Danpi 
 
Table 2: Loganin content found in LWDH water extract 
Sample concentration AUC Average RSD LC (mg/g) AD (g) 
Loganin 0.224 mg/ml 2 675 093 2 677 256 0.07 - - 
2 678 431 
2 678 245 
TC 18.875 mg/ml 5 580 558 5 515 420 2.30 2.44 2.0 
5 369 509 
5 596 193 
WR 12.500 mg/ml 5 014 786 5 109 692 1.71 3.42 1.5 
5 186 468 
5 127 821 
RSD = Relative Standard Deviation 
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Three types of adsorbents were selected for evaluation: lactose for its 
water solubility and corn starch and Avicel® PH101 for their 
adsorptibility [12, 15-16] as well as their common usage in Chinese 
herbal manufacturing [10]. The adsorbents were evaluated for their 
suitability as excipients for the LWDH tablet formula by their ability to 
change the semi-solid extract into a powder. The least desirable 
adsorbent was lactose because of its higher ratio of extract to adsorbent 
(table 3). It has also been reported that lactose is incompatible with 
loganin due to glycosidic interaction between lactose and glucose in 
loganin [10]. Thus, only corn starch and Avicel®
Adsorbent 
 PH101 were found to be 
suitable excipients in LWDH extract tablet formulation. 
 
Table 3: Quantity of adsorbent needed to convert semi-solid 







Ratio of WR 
extract to 
adsorbent 
Lactose 635 2785 1:4 
Corn 
starch 
505 1000 1:2 




Tablets must be sufficiently rugged to withstand some level of 
physical stress from handling, but they must also disintegrate within 
the required time to allow them to dissolve and be absorbed into 
body (<30 min for herbal tablets) [14-15, 17]. Two tablet 
formulations of LWDH extract, F1 and F2, were prepared for 
preliminary studies of friability and disintegration time (table 4). As 
shown in table 5, F1 tablets showed poor ruggedness in the friability 
test (10.49 % with 8 cracked tablets) but had a good disintegration 
profile (9.53±0.72 min). In contrast, F2 tablets had a very good 
friability profile (0.23 % with no broken tablets) but a poor 
disintegration test profile (>30 min). The propensity of corn starch 
to swell in water promoted disintegration of F1 tablets, but, with the 
exception of starch paste, it is not a good binder in tablets [12], 
resulting in the low friability profile of the F1 tablets. In the F2 
tablets, the excipient Avicel®
 
 PH101 had good properties both as a 
binder and as a disintegrant; however, in higher concentrations in 
tablets (20-90 %), its binding properties overwhelm the disintegrant 
properties which appear at lower concentrations (5-15 %). Based on 
the friability and disintegration time of the F1 and F2 tablets, a 
modified formulation was developed which included both 
adsorbents (table 6).  
Table 4: Initial formulations (F1 and F2) used in determining 
friability and disintegration time profiles 
Component Formulation (mg/tablet) 
F1 F2 
WR extract  500 500 
Avicel® -  PH101 500 
Corn starch 1000 - 
Purified Talcum  15.0 10.0 
Mg stearate  15.0 10.0 
Cab-osil 15.0 ® 10.0 
 
Table 5: Friability and disintegration time profiles of F1 and F2 tablet formulations of LWDH extract 
 Friability Disintegration 
Weight of 20 tablets (g)  %FR Time (min) Avg. (min) 
Before After 














 % FR = % friability; Avg. = Average, *8 tablets cracked, **No tablets broke  
 
Table 6: Composition of the modified tablet formulation of LWDH extract developed based on friability and disintegration profile tests of 
the F1 and F2 formulations 
Component Quantity (mg/tablet) Role 
WR extract 500 Active ingredient 
Avicel® 375  PH101 Adsorbent/Binder 
Corn starch 375 Adsorbent/Disintegrant 
Purified Talcum 12.5 Anti-adherent 
Mg stearate 12.5 Lubricant 
Cab-osil 12.5 ® Glidant  
 
The finished tablets, oval, 23.2 x 10.3 x 6.7 mm thick, brownish-
white in color and tasteless, were evaluated following Thai FDA 
guidelines for finished herbal products [14]. They were found to 
meet the quality control specifications of those guidelines. 
Weight variation, tablet friability, disintegration time, tablet 
hardness, and assays for loganin content are shown in Tables 7-
11; details of microbial and heavy metal contamination are 
shown in table 12.  
 
Fig. 6: Finished tablets were plain, oval, 23.2 x 10.3 x 6.7 mm 
thick, brownish-white in color, odorless and tasteless
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Table 7: Weight variation of finished tablets 
Tablet Weight (g) Tablet Weight (g) 
1 1.3061 11 1.3266 
2 1.3293 12 1.3062 
3 1.3160 13 1.3163 
4 1.3229 14 1.3056 
5 1.3261 15 1.3263 
6 1.3118 16 1.3069 
7 1.3257 17 1.3139 
8 1.3136 18 1.3174 
9 1.3286 19 1.3164 
10 1.3105 20 1.3118 
Average±SD 1.3169±0.008 g 
Variation±0.61 % 
 
Table 8: Friability profile of finished tablets 
 Weight of 20 tablets (g)  % Friability Amount of tablet breakage 
Before After 
Test 1 26.3666 26.3600 0.025 0 tablets 
Test 2 26.3689 26.3635 0.020 0 tablets 
Test 3 26.3750 26.3690 0.023 0 tablets 
Average friability±SD 0.023±0.003 % 
 
Table 9: Disintegration profile of finished tablets 
Tablet Disintegration time (min) Tablet Disintegration time (min) 
1 23.33 4 25.00 
2 24.17 5 24.66 
3 23.50 6 23.33 
Average±SD (min)24.25±0.70 
 
Table 10: Hardness of finished tablets 
Tablet Hardness (kg) Tablet Hardness (kg) 
1 11.0 6 11.0 
2 11.0 7 11.0 
3 12.0 8 11.0 
4 11.5 9 11.5 
5 11.0 10 11.0 
Average hardness±SD 11.20±0.35 kg 
 
Table 11: HPLC analysis of marker content in finished tablets 
Sample/Standard details 
Sample Weight of 10 tablets= 12.5549 g  
Average weight of 1 tablet= 1.25546 g  
Injection volume = 100 l 
Standard (loganin) Concentration= 0.224 mg/ml 
Injection volume = 10 l 
HPLC marker content  
 Injection No. AUC Average RSD Loganin Content (mg/tab) 
Loganin 1 2 668 874 2 667 850 0.05 n/a 
2 2 666 250 
3 2 668 453 
Sample 1 2 510 331 2 474 236 1.32 1.66 
2 2 465 971 
3 2 446 407 
Desired loganin content in 1 tablet (mg) 1.71 
Actual % of label amount of loganin  97.40 % 
 Note: LC = Loganin content; n/a = not applicable 
 
Stability evaluation of the finished tablets was conducted using two 
different types of containers, glass bottles with light protection 
(container B) and laminated, heat sealed packages inserted into 
glass bottles with light protection (container L), under standard 
conditions (30 °C/65 % RH) and under accelerated conditions (40 
°C/75 % RH) over a period of 90 days. Tablets in each of the 
container types showed good physical stability under both 
conditions (table 13). In terms of chemical stability, tablets in 
container B showed a degradation of the active marker (loganin) of 
more than 10 % after 30 days under accelerated conditions of 40 
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°C/75 % RH; degradation of loganin content of tablets in container L 
after 90 days was still less than 10 % under both conditions (table 
13 and fig. 7). These results indicate that moisture can affect loganin 
degradation, so exclusion of moisture from containers is important 
for minimizing degradation of quality. The laminated heat sealed 
packs in a glass bottle (container L) provided better moisture 
protection than the glass bottles alone (container B). Product shelf 
life in container L could be expected to exceed 12 months; however, 
long term stability testing is required to confirm potential shelf life 
[18]. 
 
Table 12: Quality evaluation of the LWDH finished tablets 
Parameter Guidelines and/or criteria Results 
Appearance Shape, color, odor and/or taste of the product  See fig. 6 
Weight Variation ±15 % from the average weight ±0.61 % from the average weight 
Friability Friability not more than 1 %; no detectable capping or laminating 
of tablets  
0.023±0.003 %; no capping or laminating 
detected  
Hardness n/a 11.20±0.35 kg 
Disintegration Time Not more than 30 min 24.25±0.70 min 
Loganin content 90-110 % of label amount 97.40 % of label amount 
Microbial contamination*  - Aerobic bacteria ≤ 5.0 x 103
- Enterobacteria ≤ 5.0 x 10
/g 
3
- Yeast/Fungi ≤ 5.0 x 10
/g 
3
- Escherichia coli ≤ 5.0 x 10/g 
CFU/g 
- No detection of Staphylococcus aureus in 1 g 
- No detection of Clostridium spp. in 10 g 
- No detection of Salmonella spp. in 10 g 




- Total Yeast/Fungi<10 CFU/g 
- E. coli = Not detected in 10 g 
- S. aureus = Not detected in 1 g 
- Clostridium spp. = Not detected in 
10 g  
- Salmonella spp. = Not detected in 10 
g 
Contamination of heavy 
metal* 
- Arsenic ≤ 4 ppm  
- Cadmium ≤ 0.3 ppm 
- Lead ≤ 10 ppm 
- Arsenic = 0.1 ppm 
- Cadmium = Not detected 
- Lead = Not detected 
n/a = No guidelines provided in the monograph, *Testing conducted by Regional Medical Science Center 10 (Chiang Mai). 
 
Table 13: Stability evaluation of tablets for LWDH extract 
Container Condition Appearance FRI ( %) HAR (kg) DIS (min) LOG (mg/tab) 
Day 0 
Both containers 30o See fig. 6 C/65 % RH 0.023±0.003 11.20±0.35 24.25±0.70 1.66 
40o




65 % RH 
C/ no significant change 0.013±0.006 11.25±0.43 23.83±1.56 1.65 
40o
75 % RH 
C/ no significant change 0.005±0.002 11.10±0.39 23.70±1.09 1.20 
Container L 30o
65 % RH 
C/ no significant change 0.014±0.017 11.10±0.39 24.36±0.94 1.59 
40o
75 % RH 
C/ no significant change 0.019±0.023 11.25±0.43 24.22±0.90 1.62 
Day 90 
Container B 30 o no significant change C/65 % RH 0.007±0.004 11.10±0.32 23.42±0.95 1.57 
40o no significant change C/75 % RH 0.011±0.006 11.05±0.37 24.44±0.83 1.24 
Container L 30 o no significant change C/65 % RH 0.010±0.006 11.15±0.41 23.64±1.10 1.60 
40o no significant change C/75 % RH 0.009±0.006 11.15±0.47 23.97±0.93 1.57 
 Note: FRI = Friability; HAR = Hardness; DIS = Disintegration time; LOG = Loganin content 
 
 
Fig. 7: Stability of Loganin content in LWDH tablets packed in two 
different types of containers (B = glass bottle, L = laminated, heat 
sealed package inside a glass bottle) and stored under two 
different conditions for a period of 90 days (lower limit = 90 %) 
CONCLUSION 
Extraction of standard quality LWDH formula raw materials using 
the reflux with water (WR) produces higher yields than decoction 
(TC). WR extract also contains higher loganin content per gram of 
extract than TC extract, making it the preferred method for LWDH 
tablet formulation. A suitable tablet formulation consists of dried 
water extract (38.83 %), corn starch (29.13 %), Avicel®PH101 
(29.13 %), purified talcum (0.97 %), magnesium stearate (0.97 %) 
and Cab-osil® (0.97 %) prepared by wet granulation. Exclusion of 
moisture can significantly reduce degradation of the products’ 
chemical marker, suggesting an extrapolated product shelf life of 
more than 12 months. In addition, LWDH tablets avoid problems of 
traditional formulations including high dosages, unacceptable taste 
and odor, lack of product uniformity as well as potential 
contamination with microorganisms and heavy metals, making 
tablets a good alternative for both patients and TCM practitioners. 
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